Trials using poly A:U, poly I:C, or poly(ICLC) have demonstrated clinical benefits in several tumors (NCT00694551/ NCT00058123/NCT01188096) [3], but the use of resiquimod, motolimod, and other TLR7/TLR8 agonists as immunostimulatory agents in patients with cancer have shown disappointing results in recent clinical tests [76, 81, 82]. Here, TLR7 is linked to cancer.